Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Volatility & Risk
Actinium Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.
Profitability
This table compares Actinium Pharmaceuticals and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Xenetic Biosciences | -161.63% | -49.51% | -43.99% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $81,000.00 | 643.18 | -$48.82 million | ($1.39) | -1.20 |
| Xenetic Biosciences | $2.50 million | 1.79 | -$4.14 million | ($2.38) | -1.22 |
Xenetic Biosciences has higher revenue and earnings than Actinium Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Actinium Pharmaceuticals and Xenetic Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
| Xenetic Biosciences | 0 | 1 | 0 | 0 | 2.00 |
Actinium Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 139.52%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences.
Insider & Institutional Ownership
27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
